 A second Alzheimer's drug wins FDA approval. Canunt Casella, made by Eli Lilly, is for mild or early cases of dementia caused by Alzheimer's and can delay cognitive decline in patients by reducing plaque buildup in the brain, like Lekembe, a Japanese drug that previously won approval.